Palbociclib, Trastuzumab, and Endocrine Therapy Significantly Extend Progression-Free Survival in PAM50 Luminal HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial
Posted innews Oncology

Palbociclib, Trastuzumab, and Endocrine Therapy Significantly Extend Progression-Free Survival in PAM50 Luminal HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial

The Phase II SOLTI-1303 PATRICIA trial (Cohort C) demonstrates that a triplet regimen of palbociclib, trastuzumab, and endocrine therapy significantly improves progression-free survival compared to physician's choice treatments in pretreated patients with HER2-positive, PAM50 luminal subtype advanced breast cancer.
Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer
Posted innews Oncology Pathology & Lab Medicine

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression, identifying superior combination regimens for specific genomic subgroups.
Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial
Posted inHematology-Oncology news Oncology

Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial

The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhanced antitumor efficacy and potential improvement in treatment adherence through hot flash mitigation.
High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets
Posted innews Oncology Public Health

High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets

A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets and improving treatment access could cut deaths by about a third.
SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer
Posted innews Oncology Radiology

SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer

The SUPREMO randomized trial found that postmastectomy chest‑wall irradiation reduces chest‑wall recurrence but does not improve 10‑year overall survival for intermediate‑risk breast cancer; a large real‑world analysis supports no overall survival benefit except possibly for pT3N0 disease.